CANSCAN Trial of AVF Mapping With VxWave Ultrasound Imaging System Completes Enrollment

July 29, 2025—Vexev and U.S. Renal Care announced the completion of enrollment in the CANSCAN clinical trial, a multicenter feasibility study evaluating the use of semiautonomous ultrasound scanning with Vexev’s VxWave system for arteriovenous fistula (AVF) mapping in dialysis clinics.

Vexev is an Australian-based medical device company focused on vascular imaging, and U.S. Renal Care is a United States provider of in-center and home dialysis.

The press release stated that VxWave is a robotic, tomographic, ultrasound imaging system designed for upper limb vascular imaging, integrating advanced robotics, machine learning, and ultrasound signal processing. It creates a vascular model and detailed report that potentially provides insights into vascular access points—all at the point of care.

The study has enrolled 120 patients with chronic kidney disease, advised the companies.

The CANSCAN study’s Principal Investigator is Varshi Broumand, MD, an interventional nephrologist at South Texas Renal Care Group in San Antonio, Texas.

“The VxWave ultrasound system may remove one of the biggest hurdles in the creation of vascular access,” commented Dr. Broumand in the press release. “Patients could have vascular mapping conducted in their dialysis facility, enabling a more efficient way to obtain a permanent vascular access point.”

Dr. Broumand continued, “Performing the ultrasound scans during the clinic visit would make AVF mapping more convenient and timely, and potentially avoid sending patients to additional imaging appointments.”